ClinicalTrials.gg
CompletedNCT02249182Updated Mar 2, 2020Results posted

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

A Phase 2 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 31 sites in 4 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
37th of 174
226 · median 78
Started
2014
with 16 others
Phase 2
47 of 174
none open now
Registered
135th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 37th largest by enrollment, is one of 17 that started in 2014, is one of 47 in phase 2, and was the 135th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus (HCV)-infected pediatric participants. The PK Lead-in Phase will also evaluate the safety, tolerability, and antiviral activity of 10 days of dosing of LDV/SOF FDC in HCV-infected pediatric participants.

The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate LDV/SOF FDC dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the Treatment Phase with no interruption of study drug administration. The primary objective of the Treatment Phase is to evaluate the antiviral efficacy, safety, and tolerability of LDV/SOF FDC +/- ribavirin (RBV) for 12 or 24 weeks in pediatric participants with HCV.

During screening, participants will receive placebo to match LDV/SOF FDC to assess ability to swallow tablets.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Consent of parent or legal guardian required
  • Chronic infection
  • Screening laboratory values within defined thresholds

Key Exclusion Criteria:

  • History of illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol.
  • Co-infection with , acute hepatitis A virus, or virus
  • Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)
  • Pregnant or nursing females
  • Known to study medication
  • Use of any prohibited concomitant medications as within 28 days of the Day 1 visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    12 to < 18 Years Old

    Participants between 12 to \< 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    6 to < 12 Years Old

    Participants between 6 to \< 12 years of age weighing ≥ 17 kg and \< 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    3 to < 6 Years Old

    Participants between 3 to \< 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing \< 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets). Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment. United Kingdom: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks United States/Australia/New Zealand: * HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks * HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks * HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks * HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks

    Drug: LDV/SOF · Drug: RBV

Interventions

  • DrugLDV/SOF

    LDV/SOF FDC administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugRBV

    Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight

    Also known as: REBETOL®

06

What researchers measure

Primary outcomes

  1. For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Cohorts 1 and 2 (6 to < 18 years of age): predose, 0.5, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10; Cohort 3 (3 to < 6 years of age): predose, 0.5, 2, 4, 8, and 12 hours postdose on Day 10

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase

    Time frame: Up to 24 weeks

Secondary outcomes

  1. For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA

    Time frame: Baseline; Weeks 1, 2, 4, 8, and 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase

    Time frame: Up to Day 10

  3. For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  4. For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< LLOQ at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  5. For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  6. For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough

    Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.

    Time frame: Up to 24 weeks

  7. For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse

    Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

  8. For the Treatment Phase, Change From Baseline in HCV RNA

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)

  9. For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment

    Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)

  10. For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization

    ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit.

    Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4

  11. For the Treatment Phase, Change From Baseline in Height

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24

  12. For the Treatment Phase, Change From Baseline in Weight

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24

  13. For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  14. For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  15. For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  16. For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development

    Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

    Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24

  17. Acceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1

    Participants who were able/unable to swallow placebo tablets were assessed. Participants 12 to \< 18 years old were first asked to perform the swallowability assessment using the 90/400 mg placebo tablet. If they were unable to swallow this, they were then asked to perform the swallowability assessment with 22.5/100 mg placebo tablets. Participants 6 to \< 12 years old were to be assessed with the 22.5/100 mg placebo tablets. However, 8 participants were mistakenly assessed using the 90/400 mg placebo tablet.

    Time frame: Day 1

  18. Acceptability of LDV/SOF Granules as Measured by Palatability at Day 1

    Participants who were dosed with granules were asked if they tasted the study drug. If they tasted it, then they were asked to provide a number from 0 to 100 to rate the taste of the study drug, with higher scores indicating better taste. Data was then summarized as percentage of participants choosing the following palatability categories: 1) Did not taste the study drug, 2) Tasted drug with score \> 60 to 100, 3) Tasted drug with score 40 to 60, and 4) Tasted drug with score of 0 to \< 40.

    Time frame: Day 1

07

Results

Posted Apr 24, 2019

Participant flow

Participants were enrolled at study sites in the United States, United Kingdom, Australia, and New Zealand. The first participant was screened on 05 November 2014. The last study visit occurred on 24 August 2018.

PK Lead-In Phase
Participant flow — PK Lead-In Phase
Milestone12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Started10120017
Completed10120017
Not completed00000
Treatment Phase
Participant flow — Treatment Phase
Milestone12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Started100891234
Completed96891234
Not completed40000
Withdrew: Lost to follow-up40000

Outcome measures

PrimaryFor Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Cohorts 1 and 2 (6 to < 18 years of age): predose, 0.5, 1, 2, 3, 4, 5, 8, and 12 hours postdose on Day 10; Cohort 3 (3 to < 6 years of age): predose, 0.5, 2, 4, 8, and 12 hours postdose on Day 10
Reported as:
Mean · h*ng/mL
For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF
h*ng/mLPK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 WeeksPK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 WeeksPK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks
GS-331007 (metabolite of SOF)12682.5 ± 1732.668210.3 ± 2542.4211688.9 ± 3400.79
LDV10202.4 ± 5196.497288.3 ± 4547.339316.3 ± 3280.51
SOF2175.7 ± 578.921754.4 ± 419.182495.2 ± 412.64
Statistical analysis
  • PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 105.20 · 90% CI 90.61 to 122.13
  • PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 65.76 · 90% CI 56.62 to 76.37
  • PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 94.08 · 90% CI 82.51 to 107.27
  • PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 127.18 · 90% CI 94.89 to 170.45
  • PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 82.25 · 90% CI 61.34 to 110.30
  • PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 120.46 · 90% CI 93.18 to 155.73
  • PK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 159.88 · 90% CI 137.89 to 185.37
  • PK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 129.48 · 90% CI 110.79 to 151.32
  • PK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks · Percentage geometric mean ratio: 187.76 · 90% CI 143.41 to 245.82
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase00002.9
SecondaryFor Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
Time frame:
Baseline; Weeks 1, 2, 4, 8, and 12
Reported as:
Mean · log10 IU/mL
For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
log10 IU/mLPK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 WeeksPK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 WeeksPK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks
Change at Week 1-4.34 ± 0.621-4.29 ± 0.518-4.32 ± 0.616
Change at Week 2-4.71 ± 0.651-4.55 ± 0.636-4.87 ± 0.724
Change at Week 4-4.73 ± 0.667-4.75 ± 0.702-4.92 ± 0.715
Change at Week 8-4.73 ± 0.667-4.76 ± 0.710-4.92 ± 0.715
Change at Week 12-4.73 ± 0.667-4.76 ± 0.710-4.92 ± 0.715
SecondaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
Time frame:
Up to Day 10
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
percentage of participantsPK Lead-in: 12 to < 18 Years Old - LDV/SOF 12 WeeksPK Lead-in: 6 to < 12 Years Old - LDV/SOF 12 WeeksPK Lead-in: 3 to < 6 Years Old - LDV/SOF 12 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase005.9
SecondaryFor the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)98.0 (93.0 to 99.8)98.9 (93.9 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)97.1 (84.7 to 99.9)
SecondaryFor the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< LLOQ at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)98.0 (93.0 to 99.8)98.9 (93.9 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)97.1 (84.7 to 99.9)
SecondaryFor the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)98.0 (93.0 to 99.8)98.9 (93.9 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)97.1 (84.7 to 99.9)
SecondaryFor the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough

Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough00000
SecondaryFor the Treatment Phase, Percentage of Participants Experiencing Viral Relapse

Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse01.1000
SecondaryFor the Treatment Phase, Change From Baseline in HCV RNA
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Reported as:
Mean · log10 IU/mL
For the Treatment Phase, Change From Baseline in HCV RNA
log10 IU/mL12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Change at Week 1-4.34 ± 0.634-4.27 ± 0.592-4.30 ± NA-4.54 ± 0.308-4.25 ± 0.505
Change at Week 2-4.74 ± 0.585-4.73 ± 0.544-5.09 ± NA-4.54 ± 0.308-4.80 ± 0.628
Change at Week 4-4.84 ± 0.557-4.87 ± 0.592-5.09 ± NA-4.54 ± 0.308-4.85 ± 0.628
Change at Week 8-4.85 ± 0.556-4.89 ± 0.597-5.09 ± NA-4.54 ± 0.308-4.86 ± 0.633
Change at Week 12-4.85 ± 0.556-4.89 ± 0.597-5.09 ± NA-4.54 ± 0.308-4.86 ± 0.633
Change at Week 16——-5.09 ± NA-4.54 ± 0.308—
Change at Week 20——-5.09 ± NA-4.54 ± 0.308—
Change at Week 24——-5.09 ± NA-4.54 ± 0.308—
SecondaryFor the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
Time frame:
Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Week 140.0 (30.3 to 50.3)30.3 (21.0 to 41.0)0 (0.0 to 97.5)100.0 (15.8 to 100.0)29.4 (15.1 to 47.5)
Week 275.0 (65.3 to 83.1)71.9 (61.4 to 80.9)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)78.8 (61.1 to 91.0)
Week 497.0 (91.5 to 99.4)96.6 (90.5 to 99.3)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)97.0 (84.2 to 99.9)
Week 8100.0 (96.3 to 100.0)100.0 (95.9 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)100.0 (89.4 to 100.0)
Week 12100.0 (96.3 to 100.0)100.0 (95.9 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)100.0 (89.4 to 100.0)
Week 16——100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)—
Week 20——100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)—
Week 24——100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)—
SecondaryFor the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization

ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit.

Time frame:
Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4
Reported as:
Number · percentage of participants
For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Week 172.375.7050.063.0
Week 289.884.8050.084.0
Week 493.893.10100.096.0
Week 891.390.10100.092.0
Week 1293.395.5100.0100.091.7
Week 16——100.0100.0—
Week 20——100.0100.0—
Week 24——100.0100.0—
Posttreatment Week 490.298.4—100.091.3
SecondaryFor the Treatment Phase, Change From Baseline in Height
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
Reported as:
Mean · centimeters
For the Treatment Phase, Change From Baseline in Height
centimeters12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Change at Week 10.1 ± 0.680.1 ± 0.830.3 ± NA0.7 ± 1.130.2 ± 1.24
Change at Week 20.0 ± 0.700.3 ± 0.730.5 ± NA0.5 ± 0.850.3 ± 0.72
Change at Week 40.1 ± 0.840.5 ± 0.791.2 ± NA0.6 ± 0.920.7 ± 0.79
Change at Week 80.4 ± 1.040.8 ± 0.791.3 ± NA0.8 ± 0.921.0 ± 0.82
Change at Week 120.5 ± 1.101.3 ± 0.832.1 ± NA1.1 ± 1.411.6 ± 0.98
Change at Week 16——3.2 ± NA1.4 ± 1.06—
Change at Week 20——4.3 ± NA1.6 ± 0.85—
Change at Week 24——4.3 ± NA2.5 ± 1.48—
Change at Posttreatment Week 40.8 ± 1.461.8 ± 1.044.3 ± NA2.4 ± 1.272.1 ± 1.13
Change at Posttreatment Week 121.2 ± 1.822.7 ± 0.975.0 ± NA3.4 ± 1.563.3 ± 1.18
Change at Posttreatment Week 241.8 ± 2.314.1 ± 1.397.6 ± NA5.6 ± 0.854.7 ± 1.31
SecondaryFor the Treatment Phase, Change From Baseline in Weight
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
Reported as:
Mean · kilograms
For the Treatment Phase, Change From Baseline in Weight
kilograms12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Change at Week 10.1 ± 1.000.3 ± 0.51-0.5 ± NA0.3 ± 1.340.1 ± 0.39
Change at Week 20.3 ± 1.110.4 ± 0.540.0 ± NA0.3 ± 1.770.2 ± 0.44
Change at Week 40.4 ± 1.440.5 ± 0.640.5 ± NA0.7 ± 1.910.3 ± 0.64
Change at Week 80.5 ± 1.900.8 ± 0.841.3 ± NA0.6 ± 2.330.5 ± 0.66
Change at Week 120.6 ± 2.321.1 ± 1.272.1 ± NA0.9 ± 2.900.6 ± 0.70
Change at Week 16——1.6 ± NA1.2 ± 3.68—
Change at Week 20——2.2 ± NA1.8 ± 3.96—
Change at Week 24——3.1 ± NA2.4 ± 3.68—
Change at Posttreatment Week 40.9 ± 2.701.4 ± 1.481.8 ± NA2.2 ± 3.681.1 ± 1.09
Change at Posttreatment Week 121.6 ± 3.482.1 ± 1.873.1 ± NA3.7 ± 2.901.2 ± 0.93
Change at Posttreatment Week 243.2 ± 4.383.5 ± 2.754.5 ± NA5.7 ± 1.412.0 ± 1.57
SecondaryFor the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
End of Treatment — No Change355210
End of Treatment — Increase110
End of Treatment — Decrease010
Posttreatment Week 12 — No Change32519
Posttreatment Week 12 — Increase320
Posttreatment Week 12 — Decrease010
Posttreatment Week 24 — No Change28489
Posttreatment Week 24 — Increase741
Posttreatment Week 24 — Decrease010
SecondaryFor the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
Participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
End of Treatment — No Change345210
End of Treatment — Increase110
End of Treatment — Decrease010
Posttreatment Week 12 — No Change33509
Posttreatment Week 12 — Increase240
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change294710
Posttreatment Week 24 — Increase660
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
End of Treatment — No Change523421
End of Treatment — Increase920
End of Treatment — Decrease100
Posttreatment Week 12 — No Change453122
Posttreatment Week 12 — Increase1530
Posttreatment Week 12 — Decrease000
Posttreatment Week 24 — No Change402722
Posttreatment Week 24 — Increase2180
Posttreatment Week 24 — Decrease000
SecondaryFor the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development

Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.

Time frame:
Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
Reported as:
Count of participants · Participants
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
Participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
End of Treatment — No Change533121
End of Treatment — Increase850
End of Treatment — Decrease100
Posttreatment Week 12 — No Change492521
Posttreatment Week 12 — Increase1181
Posttreatment Week 12 — Decrease010
Posttreatment Week 24 — No Change432121
Posttreatment Week 24 — Increase18141
Posttreatment Week 24 — Decrease000
SecondaryAcceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1

Participants who were able/unable to swallow placebo tablets were assessed. Participants 12 to \< 18 years old were first asked to perform the swallowability assessment using the 90/400 mg placebo tablet. If they were unable to swallow this, they were then asked to perform the swallowability assessment with 22.5/100 mg placebo tablets. Participants 6 to \< 12 years old were to be assessed with the 22.5/100 mg placebo tablets. However, 8 participants were mistakenly assessed using the 90/400 mg placebo tablet.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Acceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1
percentage of participants12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF±RBV 12 or 24 Weeks
Able to Swallow 90/400 mg Placebo Tablet89.0100.0
Unable to Swallow 90/400 mg Placebo Tablet11.00
Able to Swallow 22.5/100 mg Placebo Tablet72.798.8
Unable to Swallow 22.5/100 mg Placebo Tablet27.31.2
SecondaryAcceptability of LDV/SOF Granules as Measured by Palatability at Day 1

Participants who were dosed with granules were asked if they tasted the study drug. If they tasted it, then they were asked to provide a number from 0 to 100 to rate the taste of the study drug, with higher scores indicating better taste. Data was then summarized as percentage of participants choosing the following palatability categories: 1) Did not taste the study drug, 2) Tasted drug with score \> 60 to 100, 3) Tasted drug with score 40 to 60, and 4) Tasted drug with score of 0 to \< 40.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Acceptability of LDV/SOF Granules as Measured by Palatability at Day 1
percentage of participants3 to < 6 Years Old - LDV/SOF 12 Weeks
Did not taste the study drug41.2
Tasted drug with score > 60 to 10017.6
Tasted drug with score 40 to 6011.8
Tasted drug with score of 0 to < 4029.4

Adverse events

Collected over Adverse Events (AEs): First dose date up to Week 12 or 24 (depending on group) plus 30 days (includes AEs occurring during the PK Lead-in Phase); All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 to < 18 Years Old - LDV/SOF 12 Weeks0/100 (0%)0/100 (0%)62/100 (62%)
6 to < 12 Years Old - LDV/SOF 12 Weeks0/89 (0%)1/89 (1.1%)54/89 (60.7%)
6 to < 12 Years Old - LDV/SOF 24 Weeks0/1 (0%)0/1 (0%)1/1 (100%)
6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks0/2 (0%)0/2 (0%)2/2 (100%)
3 to < 6 Years Old - LDV/SOF 12 Weeks0/34 (0%)0/34 (0%)22/34 (64.7%)
Most frequent serious events
Most frequent serious events
Event12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
Abdominal painGastrointestinal disorders0/1001/890/10/20/34
GastroenteritisInfections and infestations0/1001/890/10/20/34
Tooth abscessInfections and infestations0/1001/890/10/20/34
Most frequent other events
Showing 10 of 33
Most frequent other events
Event12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 Weeks
CoughRespiratory, thoracic and mediastinal disorders10/10011/891/11/27/34
EpistaxisRespiratory, thoracic and mediastinal disorders2/1002/891/10/22/34
Nasal congestionRespiratory, thoracic and mediastinal disorders6/1005/891/10/22/34
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/1003/891/10/26/34
Ear painEar and labyrinth disorders0/1002/890/11/20/34
Mouth ulcerationGastrointestinal disorders0/1002/890/11/21/34
NauseaGastrointestinal disorders11/1009/890/11/21/34
VomitingGastrointestinal disorders12/10012/890/11/28/34
FatigueGeneral disorders13/10013/890/11/22/34
PyrexiaGeneral disorders2/10015/890/11/27/34

Baseline characteristics

Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
Mean15 ± 1.79 ± 1.611 ± NA9 ± 2.84 ± 0.711 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
Female63361124125
Male37530110101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
White91701227191
Black or African American7700115
Other050049
Asian250029
Native Hawaiian or Pacific Islander020002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
Hispanic or Latino13900628
Not Hispanic or Latino85751228191
Not Disclosed250007
Region of Enrollment
Region of Enrollment(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
New Zealand040004
United States91700029190
United Kingdom1902315
Australia8610217
HCV Genotype
HCV Genotype(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
Genotype 1100871033221
Genotype 3000202
Genotype 4020013
Cirrhosis Status
Cirrhosis Status(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
Yes111003
No4333021492
Unknown56550020131
IL28b Status
IL28b Status(Participants)12 to < 18 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 12 Weeks6 to < 12 Years Old - LDV/SOF 24 Weeks6 to < 12 Years Old - LDV/SOF+RBV 24 Weeks3 to < 6 Years Old - LDV/SOF 12 WeeksTotal
CC2423001057
CT53530216124
TT231210642
Missing010023

2 further baseline measures are reported on the registry.

08

Study locations

31 sites
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • San Antonio, Texas, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Newcastle, New South Wales, Australia
  • Westmead, New South Wales, Australia
  • Parkville, Victoria, Australia
  • Auckland, New Zealand
  • Birmingham, England, United Kingdom
  • Leeds, England, United Kingdom
  • London, England, United Kingdom
  • Glasgow, Scotland, United Kingdom
09

References and documents

Publications

  • Kirby B, German P, Kanwar B, Ni L, Lakatos I, Ling J, Mathias A. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Adolescents. Hepatology 2015;62 (S1): 1040A-1041A
  • Garrison KL, Mathias A, Kersey K, Kanwar B, Ni L, Jain A, et al. Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to < 12 Years Old. Hepatology 2016;64 (S1): 436A
  • Schwarz K, Murray KF, Rosenthal P, Bansal S, Lin CH, Ni L, et al. High Rates of SVR12 in Adolescents Treated with the Combination of Ledipasvir/Sofosbuvir. J Hepatol 2016; 64 (2): S184-S185
  • K.F. Murray, W. Balistreri, S. Bansal, S. Whitworth, H. Evans, R.P. Gonzalez-Peralta, et al. Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infection. J Hepatol 2017;66: S33-S62
  • Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, Massetto B, Zhu Y, Kanwar B, German P, Svarovskaia E, Brainard DM, Wen J, Gonzalez-Peralta RP, Jonas MM, Schwarz K. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19. PubMed 27997679 ↗
  • Younossi ZM, Stepanova M, Balistreri W, Schwarz K, Murray KF, Rosenthal P, Bansal S, Hunt S. Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):112-116. doi: 10.1097/MPG.0000000000001754. PubMed 28957984 ↗
  • Begley R, Meng A, Massetto B, Shao J, Ling J, and Mathias A. Pharmacokinetics of Once Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3 to <6 Years Old. Hepatology 2018;68 (S1): 582A.
  • Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 Years Old with Chronic Hepatitis C Virus Infection. Hepatology 2018;68 (S1): 116A-117A.
  • Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, Wen J, Massetto B, Kersey K, Shao J, Garrison KL, Parhy B, Brainard DM, Arnon R, Gillis LA, Jonas MM, Lin CH, Narkewicz MR, Schwarz K, Rosenthal P. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018 Dec;68(6):2158-2166. doi: 10.1002/hep.30123. Epub 2018 Nov 17. PubMed 30070726 ↗
  • Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology. 2020 Feb;71(2):422-430. doi: 10.1002/hep.30830. Epub 2019 Aug 19. PubMed 31220349 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jun 2018, 43 months.

Results were first posted in Apr 2019, 10 months after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 43 months is above that.

Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Sep 25, 2014
StartActual
Nov 5, 2014
Primary completionActual
Jun 15, 2018
CompletionActual
Aug 24, 2018
Results first posted
Apr 24, 2019
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02249182
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Nov 5, 2014
Primary completion
Jun 15, 2018
Completion
Aug 24, 2018
Results posted
Apr 24, 2019
Last update
Mar 2, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion